Cheng-I Wang

About

My research interests focus on therapeutic protein and antibody engineering, synthetic biology, and immunotherapy, with the goal of advancing strategies for disease treatment. Through antibody engineering, we aim to design next-generation T-cell engagers and antibody–drug conjugates capable of addressing diverse disease indications. In addition, we have successfully engineered an extensive panel of antibodies targeting immune checkpoints to effectively reactivate the immune system and combat tumors in mouse models. We also developed a unique strategy to activate anti-cancer cytokine pathways through a bispecific receptor agonist antibody design. Building on the antibody engineering technologies established in our laboratory, we have further embarked on the development of Chimeric Antigen Receptor (CAR) T cells with a particular focus on overcoming tumor heterogeneity. Altogether, these studies reflect our ongoing efforts to use antibody and cell engineering to open new possibilities for treating cancer and other diseases.

Work

Singapore Immunology Network

Singapore

Education

Washington University in St Louis
United States of America

PhD

Publications

A combinatorial and computational Tandem approach towards a universal therapeutics against ACE2-mediated coronavirus infections

Published by

iScience

Summary

journal-article

Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus

Published by

Communications Biology

Summary

journal-article

Defining neutralization and allostery by antibodies against COVID-19 variants

Published by

Nature Communications

Summary

journal-article

A nonstructural protein 1 capture enzyme-linked immunosorbent assay specific for dengue viruses

Published by

PLOS ONE

Summary

journal-article

Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants

Published by

mAbs

Summary

journal-article

Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia

Published by

Cell

Summary

journal-article

Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore

Published by

npj Vaccines

Summary

journal-article

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians

Published by

The Lancet Regional Health - Western Pacific

Summary

journal-article

Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells

Published by

Molecular Cancer Therapeutics

Summary

journal-article

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Published by

Nature Communications

Summary

journal-article